ABUS logo

ARBUTUS BIOPHARMA CORP

ABUSNASDAQ
🏆 #2625 by market capEarnings Mar 4US Equity
$4.02▼ $0.05 (−1.23%)
Market closed · at close
🔔
Track ABUS
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 1.2%
7d▼ 1.7%
14d▲ 10.0%
30d▼ 4.3%
ytd▼ 16.6%
1y▼ 6.5%
🏦Market Cap
$616M
Small Cap
📈Revenue Growth (YoY)
128.2%
High Growth
📊Gross Margin
100.0%
High
💵FCF Margin
121.8%
Strong
⚖️P/S Ratio
3.4x
Fair
Otter Score
80
Strong

Trading Snapshot

Day Range
$3.97 – $4.09
52-Week Range
$3.50 – $5.45
Volume (shares)
2,993,383
Avg Volume (shares)
—
Shares Outstanding
153.3M
Next Earnings
2027-03-04

Fundamentals Snapshot

Annual Revenue
$14M
Last Q Revenue
$299,000
P/E Ratio
3.6
P/S Ratio
3.4x
EPS (TTM)
$1.11
Dividend Yield
0.00%
Dilution (1yr)
+0.9%
ABUS logo

ARBUTUS BIOPHARMA CORP

ABUS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$14M▲ +128.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
97.4%▼ −2.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$27M▼ −64.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$40M▼ −39.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
191.6M▲ +0.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$14M▼ −$16M YoY
StockOtter · stockotter.space

About ARBUTUS BIOPHARMA CORP

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Strong
80/100

Analyst Ratings

ⓘ
Consensus
Buy
7 analysts
Strong Buy3
Buy3
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

GlobeNewsWire·12d ago

Arbutus Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Maintained strong financial position with cash, cash equivalents and marketable securities of $337.5M as of September 30, 2026, including receipt of cash dividend of $67.3M from Genevant

GlobeNewsWire·Oct 22

Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor

WARMINSTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that

Seeking Alpha·Oct 8

Arbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV Cure

Arbutus Biopharma is rated Buy, leveraging a $179.1M Moderna settlement and a 46M share buyback to enhance per-share value. Imdusiran, ABUS's RNAi asset for chronic hepatitis B, targets a functional cure and could genera

Defense World·Oct 2

Arbutus Biopharma (NASDAQ:ABUS) Stock Price Up 5.3% – Here’s What Happened

Arbutus Biopharma Corporation (NASDAQ: ABUS - Get Free Report) shot up 5.3% during mid-day trading on Wednesday. The company traded as high as $4.93 and last traded at $4.9370. Approximately 1,416,271 shares were traded

GlobeNewsWire·Oct 1

Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

WARMINSTER, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the

GlobeNewsWire·Sep 30

Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

WARMINSTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the